Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Syneron sublative technology earns CE mark for stretch mark and acne scar treatment

Syneron Medical has announced that its proprietary Sublative technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne scars.

The new treatment protocols are now available on all of the Syneron Sublative compatible systems, which include elos Plus, eTwo and eMatrix.

With its new CE Mark clearance, Sublative has been shown to be an effective and safe way to reduce the appearance of stretch marks, acne scars and other skin irregularities in all skin types with minimal side effects, discomfort or downtime.

The unique patented technology uses fractionated bi-polar radiofrequency directed to the skin in the form of a matrix. Due to its unique design, energy is deposited in the skin to initiate a healing response with minimal epidermal disruption.

Patients benefit from a comfortable treatment with significant outcomes avoiding the potential complications of more aggressive treatments. After treatment with Sublative, the appearance of stretch marks and acne scars are greatly reduced.

"We have extensively studied the Sublative approach in the treatment of striae and found a noticeable and measurable improvement in the depth, width and color of striae after very few treatments," states Maurice Adatto , M.D., Dermatologic Surgeon, Geneva, Switzerland , founder & Medical Director of SKINPULSE Derm & Laser Centres, Lecturer at Bern University Hospital.

The typical Sublative protocol consists of three to five treatments, spaced four to six weeks apart. Post treatment, patients can expect tone and texture improvements as a result of increased levels of collagen and elastin and new healthy skin cells, which are produced.

The addition of stretch mark treatment further expands Syneron’s clinical utility and will allow physician customers to address a large segment of the aesthetic market.

Syneron CEO Amit Meridor noted that the company received very positive physician and patient feedback on the Sublative technology since its introduction in 2009.

"This patented fractional bi-polar radio frequency technology delivers excellent outcomes with little-to-no downtime and is a safe and more effective treatment alternative for all skin tones. We continue to create innovation solutions that further drive the aesthetic industry forward," Meridor added.

Syneron will unveil the Striae and acne scars treatment protocols for its Sublative compatible platforms at the 12th Annual Anti-Aging Medicine World Congress in Monte Carlo, Monaco from 3 April to 5 April 2014.